Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Dicerna Pharmaceutic (DRNA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 773,461
  • Shares Outstanding, K 62,730
  • Annual Sales, $ 2,280 K
  • Annual Income, $ -60,050 K
  • 36-Month Beta 2.39
  • Price/Sales 339.70
  • Price/Cash Flow N/A
  • Price/Book 4.87

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate -0.23
  • Number of Estimates 5
  • High Estimate -0.11
  • Low Estimate -0.37
  • Prior Year -0.90
  • Growth Rate Est. (year over year) +74.44%

Price Performance

See More
Period Period Low Period High Performance
1-Month
12.05 +0.83%
on 12/14/18
15.21 -20.12%
on 12/03/18
-0.67 (-5.23%)
since 11/14/18
3-Month
11.70 +3.85%
on 10/19/18
17.85 -31.93%
on 09/17/18
-5.54 (-31.32%)
since 09/14/18
52-Week
6.80 +78.68%
on 12/19/17
17.98 -32.42%
on 09/14/18
+4.84 (+66.21%)
since 12/14/17

Most Recent Stories

More News
Analysis: Positioning to Benefit within Dicerna Pharmaceuticals, Sun Life Financial, Autodesk, Eagle Pharmaceuticals, Curis, and Accenture -- Research Highlights Growth, Revenue, and Consolidated Results

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Dicerna Pharmaceuticals, Inc....

DRNA : 12.15 (-1.46%)
ADSK : 131.50 (-3.00%)
CRIS : 0.84 (+5.00%)
EGRX : 43.94 (+1.93%)
SLF : 33.48 (-0.80%)
ACN : 155.53 (-2.95%)
Dicerna to Highlight Lead GalXC(TM) Pipeline Programs, Collaborations, and Advances to GalXC Technology Platform at R&D Day 2018

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, will host an R&D Day today in New York City to...

DRNA : 12.15 (-1.46%)
Dicerna Pharmaceuticals (DRNA) Reports Q3 Loss, Misses Revenue Estimates

Dicerna Pharmaceuticals (DRNA) delivered earnings and revenue surprises of -45.83% and -7.26%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?...

DRNA : 12.15 (-1.46%)
Dicerna Reports Third Quarter 2018 Financial and Operating Results and Provides Corporate Update

--Entered into Strategic Collaborations with Lilly and Alexion to Discover and Develop RNAi Therapies Using Dicerna's GalXC(TM) Technology Platform

DRNA : 12.15 (-1.46%)
Biotech Stock Roundup: Celgene, Amgen, Vertex Impress in Q3, DRNA Soars on LLY Deal

Impressive third-quarter results by most biotech bigwigs were the key highlights of the week. Most companies upped their guidance.

DRNA : 12.15 (-1.46%)
CELG : 68.20 (-2.21%)
RARE : 46.01 (-2.75%)
VRTX : 170.06 (-1.94%)
GILD : 65.57 (-2.64%)
REGN : 381.17 (+0.70%)
AMGN : 192.07 (-2.76%)
ALXN : 109.43 (-2.67%)
Dicerna to Report Third Quarter 2018 Financial Results and Host Conference Call on November 5, 2018

Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Company will release...

DRNA : 12.15 (-1.46%)
Lilly and Dicerna Announce RNAi Licensing and Research Collaboration

Eli Lilly and Company (NYSE: LLY) and Dicerna Pharmaceuticals (NASDAQ: DRNA) today announced a global licensing and research collaboration focused on the discovery, development and commercialization of...

DRNA : 12.15 (-1.46%)
LLY : 111.93 (-2.55%)
Dicerna Announces Late-Breaking Data Supporting Use of DCR-PHXC in Adults with Primary Hyperoxaluria Types 1 and 2 (PH1 and PH2)

--Reductions in Urinary Oxalate, Combined with Favorable Safety/Tolerability Profile, Lay Groundwork for Planned DCR-PHXC Phase 2/3 Registration Trial, Anticipated to Begin in First Quarter of 2019

DRNA : 12.15 (-1.46%)
BKDCF : 0.4897 (+13.88%)
Alexion and Dicerna Announce Collaboration to Discover and Develop RNAi Therapies for Complement-Mediated Diseases

--- Agreement provides Alexion with exclusive worldwide licenses as well as development and commercial rights for two preclinical GalXC RNAi molecules, with option for two additional candidates -

DRNA : 12.15 (-1.46%)
ALXN : 109.43 (-2.67%)
Dicerna Announces Late-Breaking Data from the PHYOX Phase 1 Clinical Trial of DCR-PHXC Will Be Presented at ASN Kidney Week 2018

Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that late-breaking data from...

DRNA : 12.15 (-1.46%)
BKDCF : 0.4897 (+13.88%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade DRNA with:

Business Summary

Dicerna Pharmaceuticals, Inc. is focused on the discovery and development of innovative treatments for rare inherited diseases involving the liver and for cancers. The company uses its proprietary RNA interference technology platform primarily in the United States and internationally. Dicerna Pharmaceuticals,...

See More

Key Turning Points

2nd Resistance Point 13.00
1st Resistance Point 12.58
Last Price 12.15
1st Support Level 11.89
2nd Support Level 11.62

See More

52-Week High 17.98
Fibonacci 61.8% 13.71
Fibonacci 50% 12.39
Last Price 12.15
Fibonacci 38.2% 11.07
52-Week Low 6.80

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar